Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ertapenem Sodium

FDA-approved product (injectable, intramuscular, intravenous), marketed as Ertapenem Sodium, Invanz.

Registered studies
50+
Lab records
186
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Ertapenem Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Bacterial pneumonia
  • Community-Acquired Infections
  • Gram-negative bacterial infections
  • Infection
  • Osteomyelitis
  • Staphylococcal skin infections
  • Streptococcal infection
  • Surgical Wound Infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Carbapenems
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01DH03

Repurposing investigation

Ertapenem Sodium is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA98.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli98.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. A stereoisomer of this medicine was in the model's training data.
  • K. pneumoniae99.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis55.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • K. pneumoniae: measured active in 141 of 186 lab records
Open Ertapenem Sodium in ChEMBL Registered studies below
Show the latest 150 of 186 laboratory records, with sources

Loading records…

Every record is in ChEMBL, linked above. “Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ertapenem Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • New AntiBiotic Treatment Options for Uncomplicated Anogenital GOnorrhoea

    NCT03294395 · start 2017-09-18

    Registered record
    Registry ID
    NCT03294395
    Conditions
    Gonorrhea
    Interventions
    Ertapenem 1000 MG; Fosfomycin Oral Suspension; Gentamicin Sulfate, Injectable; Ceftriaxone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-09-18
    Completion
    2020-06-05
    Enrolment
    346

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGonorrhea
    InterventionErtapenem 1000 MG; Fosfomycin Oral Suspension; Gentamicin Sulfate, Injectable; Ceftriaxone
    PhasePhase 3
    Registry statusCompleted

  • Antibiotics vs. Placebo in Acute Uncomplicated Appendicitis

    NCT03234296 · start 2017-08-09

    Registered record
    Registry ID
    NCT03234296
    Conditions
    Acute Appendicitis
    Interventions
    Ertapenem; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Enrolling by invitation
    Start
    2017-08-09
    Completion
    2029-08-30
    Enrolment
    147

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Appendicitis
    InterventionErtapenem; Placebo
    PhaseNot applicable
    Registry statusEnrolling by invitation

  • Ertapenem Administered Subcutaneously Versus Intravenously

    NCT03218800 · start 2017-06-01

    Registered record
    Registry ID
    NCT03218800
    Conditions
    Urinary Tract Infections
    Interventions
    Ertapenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2017-06-01
    Completion
    2021-02-28
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Tract Infections
    InterventionErtapenem
    PhasePhase 3
    Registry statusTerminated

  • Acute Appendicitis and Microbiota - Etiology of Appendicitis and Antibiotic Therapy Effects

    NCT03257423 · start 2017-04-04

    Registered record
    Registry ID
    NCT03257423
    Conditions
    Acute Appendicitis
    Interventions
    Ertapenem followed by levofloxacin and metronidazole; Moxifloxacin; Appendectomy; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2017-04-04
    Completion
    2025-12-31
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Appendicitis
    InterventionErtapenem followed by levofloxacin and metronidazole; Moxifloxacin; Appendectomy; Placebo
    PhaseNot applicable
    Registry statusUnknown

  • Antibiotic Prophylaxis in Patients Undergoing GVO

    NCT04140578 · start 2017-01-28

    Registered record
    Registry ID
    NCT04140578
    Conditions
    Gastric Varix; Sepsis; Liver Cirrhoses; Fever
    Interventions
    Ertapenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2017-01-28
    Completion
    2030-12-31
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastric Varix; Sepsis; Liver Cirrhoses; Fever
    InterventionErtapenem
    PhasePhase 4
    Registry statusRecruiting

  • Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections

    NCT03032510 · start 2017-01

    Registered record
    Registry ID
    NCT03032510
    Conditions
    Complicated Urinary Tract Infections
    Interventions
    Eravacycline; Ertapenem; Placebo; Levofloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-01
    Completion
    2018-01
    Enrolment
    1,205

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionComplicated Urinary Tract Infections
    InterventionEravacycline; Ertapenem; Placebo; Levofloxacin
    PhasePhase 3
    Registry statusCompleted

  • Ertapenem in Patients With Urosepsis

    NCT03859362 · start 2017-01

    Registered record
    Registry ID
    NCT03859362
    Conditions
    Patients With Urosepis and Received Ertapenem for Treatment
    Interventions
    Ertapenem Injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2017-01
    Completion
    2021-12-31
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPatients With Urosepis and Received Ertapenem for Treatment
    InterventionErtapenem Injection
    PhasePhase 4
    Registry statusUnknown

  • Sitafloxacin and Ertapenem Treatment for Acute Urinary Tract Infection Caused by E. Coli or K. Pneumoniae in Post-kidney Transplantation Patients

    NCT02729116 · start 2016-07

    Registered record
    Registry ID
    NCT02729116
    Conditions
    Anti-Infective Agents, Urinary; Escherichia Coli Infections; Klebsiella Infections; Kidney Transplantation; Urinary Tract Infections
    Interventions
    Sitafloxacin; Ertapenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2016-07
    Completion
    2024-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnti-Infective Agents, Urinary; Escherichia Coli Infections; Klebsiella Infections; Kidney Transplantation +1 more
    InterventionSitafloxacin; Ertapenem
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Pharmacokinetics and Optimal Dose of Ertapenem in Hemodialysis Patients

    NCT02159859 · start 2014-12

    Registered record
    Registry ID
    NCT02159859
    Conditions
    End Stage Renal Disease
    Interventions
    Ertapenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-12
    Completion
    2016-04
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEnd Stage Renal Disease
    InterventionErtapenem
    PhasePhase 2
    Registry statusCompleted

  • Pharmacokinetics of Ertapenem in Patients Aged Over 75

    NCT02505386 · start 2014-08

    Registered record
    Registry ID
    NCT02505386
    Conditions
    Infections
    Interventions
    Ertapenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-08
    Completion
    2016-08
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfections
    InterventionErtapenem
    PhasePhase 4
    Registry statusCompleted

  • Assessment of Prostatic Tissue Concentration of Ertapenem After a Pre-operative Administration

    NCT02041767 · start 2013-12

    Registered record
    Registry ID
    NCT02041767
    Conditions
    Benign Prostatic Hyperplasia (BPH) Requiring Surgical Resection
    Interventions
    Ertapenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-12
    Completion
    2015-06
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBenign Prostatic Hyperplasia (BPH) Requiring Surgical Resection
    InterventionErtapenem
    PhasePhase 4
    Registry statusCompleted

  • Antibiotics for Klebsiella Liver Abscess Study

    NCT01723150 · start 2013-11-05

    Registered record
    Registry ID
    NCT01723150
    Conditions
    Liver Abscess, Pyogenic
    Interventions
    Ciprofloxacin; Ceftriaxone; Trimethoprim/sulfamethoxazole; Ertapenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-11-05
    Completion
    2018-01-16
    Enrolment
    152

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Abscess, Pyogenic
    InterventionCiprofloxacin; Ceftriaxone; Trimethoprim/sulfamethoxazole; Ertapenem
    PhasePhase 4
    Registry statusCompleted

  • Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Complicated Intra-abdominal Infections

    NCT01844856 · start 2013-08

    Registered record
    Registry ID
    NCT01844856
    Conditions
    Complicated Intra-abdominal Infections
    Interventions
    Eravacycline; Ertapenem; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-08
    Completion
    2014-08
    Enrolment
    541

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionComplicated Intra-abdominal Infections
    InterventionEravacycline; Ertapenem; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Antibiotic Stewardship in Small Hospitals

    NCT03245879 · start 2013-07

    Registered record
    Registry ID
    NCT03245879
    Conditions
    Inappropriate Prescribing; Antibiotic Stewardship; Anti-Bacterial Agents
    Interventions
    Program 1; Program 2; Program 3
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2013-07
    Completion
    2015-06
    Enrolment
    30,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInappropriate Prescribing; Antibiotic Stewardship; Anti-Bacterial Agents
    InterventionProgram 1; Program 2; Program 3
    PhaseNot applicable
    Registry statusCompleted

  • Sitafloxacin and Ertapenem Treatment for Acute Pyelonephritis Caused by Escherichia Coli

    NCT02537847 · start 2012-11

    Registered record
    Registry ID
    NCT02537847
    Conditions
    Infection Due to Escherichia Coli; Acute Pyelonephritis
    Interventions
    Sitafloxacin; Ertapenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2012-11
    Completion
    2016-05
    Enrolment
    96

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection Due to Escherichia Coli; Acute Pyelonephritis
    InterventionSitafloxacin; Ertapenem
    PhasePhase 2
    Registry statusUnknown